| Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy … EB Garon, TE Ciuleanu, O Arrieta, K Prabhash, KN Syrigos, T Goksel, ... The Lancet 384 (9944), 665-673, 2014 | 1381 | 2014 |
| Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study GV Scagliotti, V Hirsh, S Siena, DH Henry, PJ Woll, C Manegold, ... Journal of Thoracic Oncology 7 (12), 1823-1829, 2012 | 366 | 2012 |
| Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial T Gupta, JP Agarwal, S Jain, R Phurailatpam, S Kannan, S Ghosh-Laskar, ... Radiotherapy and Oncology 104 (3), 343-348, 2012 | 359 | 2012 |
| Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer V Noronha, VM Patil, A Joshi, N Menon, A Chougule, A Mahajan, A Janu, ... Journal of Clinical Oncology 38 (2), 124-136, 2020 | 355 | 2020 |
| Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial V Noronha, A Joshi, VM Patil, J Agarwal, S Ghosh-Laskar, A Budrukkar, ... Journal of Clinical Oncology 36 (11), 1064-1072, 2018 | 312 | 2018 |
| Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial V Murthy, P Maitre, S Kannan, G Panigrahi, R Krishnatry, G Bakshi, ... Journal of Clinical Oncology 39 (11), 1234-1242, 2021 | 215 | 2021 |
| Crizotinib: A comprehensive review A Sahu, K Prabhash, V Noronha, A Joshi, S Desai South Asian journal of cancer 2 (2), 91, 2013 | 195 | 2013 |
| Epidemiology of lung cancer in India: Focus on the differences between non-smokers and smokers: A single-centre experience V Noronha, R Dikshit, N Raut, A Joshi, CS Pramesh, K George, ... Indian journal of cancer 49 (1), 74-81, 2012 | 188 | 2012 |
| The Chennai Declaration: a roadmap to tackle the challenge of antimicrobial resistance A Ghafur, D Mathai, A Muruganathan, JA Jayalal, R Kant, D Chaudhary, ... Indian Journal of Cancer 50 (1), 71-73, 2013 | 181 | 2013 |
| Weekly low‐dose versus three‐weekly high‐dose cisplatin for concurrent chemoradiation in locoregionally advanced non‐nasopharyngeal head and neck cancer: a systematic review … P Szturz, K Wouters, N Kiyota, M Tahara, K Prabhash, V Noronha, ... The oncologist 22 (9), 1056-1066, 2017 | 169 | 2017 |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2016 | 160 | 2016 |
| Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non‐small cell lung cancer or colorectal cancer: a randomized, double‐blind, placebo … AJ Stewart Coats, GF Ho, K Prabhash, S von Haehling, J Tilson, R Brown, ... Journal of cachexia, sarcopenia and muscle 7 (3), 355-365, 2016 | 149 | 2016 |
| Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers VM Patil, K Prabhash, V Noronha, A Joshi, V Muddu, S Dhumal, S Arya, ... Oral oncology 50 (10), 1000-1004, 2014 | 147 | 2014 |
| Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity A Chougule, K Prabhash, V Noronha, A Joshi, A Thavamani, P Chandrani, ... PloS one 8 (10), e76164, 2013 | 118 | 2013 |
| Actionable activating oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations KB Pahuja, TT Nguyen, BS Jaiswal, K Prabhash, TM Thaker, K Senger, ... Cancer cell 34 (5), 792-806. e5, 2018 | 114 | 2018 |
| Lung cancer in the Indian subcontinent V Noronha, R Pinninti, VM Patil, A Joshi, K Prabhash South Asian journal of cancer 5 (03), 095-103, 2016 | 113 | 2016 |
| A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer VM Patil, V Noronha, A Joshi, J Agarwal, S Ghosh‐Laskar, A Budrukkar, ... Cancer 125 (18), 3184-3197, 2019 | 103 | 2019 |
| Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines A D’cruz, T Lin, AK Anand, D Atmakusuma, MJ Calaguas, I Chitapanarux, ... Oral oncology 49 (9), 872-877, 2013 | 100 | 2013 |
| Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. K Prabhash, A Medhekar, N Ghadyalpatil, V Noronha, S Biswas, ... Indian journal of cancer 47 (2), 2010 | 100 | 2010 |
| Low-dose vs. high-dose cisplatin: lessons learned from 59 chemoradiotherapy trials in head and neck cancer P Szturz, K Wouters, N Kiyota, M Tahara, K Prabhash, V Noronha, ... Frontiers in oncology 9, 86, 2019 | 90 | 2019 |
Vanita NoronhaProfessor, Tata Memorial HospitalVerified email at tmc.gov.in
